British Journal of Clinical Pharmacology

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
pp. 111-116(6)
Authors: Ouellet, Daniele; Hsu, Ann; Qian, Jiang; Locke, Charles S.; Eason, Carolyn J.; Cavanaugh, John H.; Leonard, John M.; Granneman, G. Richard

Population pharmacokinetics of ondansetron: a covariate analysis
pp. 117-125(9)
Authors: de Alwis, D. P.; Aarons, L.; Palmer, J. L.

Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study
pp. 133-137(5)
Authors: Lipscomb, G.R.; Wallis, N.; Armstrong, G.; Rees, W.D.W.

The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils
pp. 139-145(7)
Authors: Taylor, M.L.; Ilton, M.K.; Misso, N.L.A.; Watkins, D.N.; Hung, J.; Thompson, P.J.

Bias in reporting clinical trials
pp. 147-150(4)
Author: Bardy, A.H.

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
pp. 151-156(6)
Authors: Ridge, Susan A.; Sludden, Julieann; Brown, Oliver; Robertson, Leigh; Wei, Xiaoxiong; Sapone, Andrea; Fernandez-Salguero, Pedro M.; Gonzalez, Frank J.; Vreken, Peter; van Kuilenburg, Andre BP; van Gennip, Albert H.; McLeod, Howard L.

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
pp. 151-156(6)
Authors: Ridge, S.A.; Sludden, J.; Brown, O.; Robertson, L.; Wei, X.; Sapone, A.; Fernandez-Salguero, P.M.; Gonzalez, F.J.; Vreken, P.; van Kuilenburg, A.B.; van Gennip, A.H.; McLeod, H.L.

A new regimen for starting warfarin therapy in out-patients
pp. 157-161(5)
Authors: Oates, A.; Jackson, P. R.; Austin, C. A.; Channer, K. S.

A new regimen for starting warfarin therapy in out-patients
pp. 157-161(5)
Authors: Oates, A.; Jackson, P.R.; Austin, C.A.; Channer, K.S.

Constant rate infusion of vancomycin in premature neonates: a new dosage schedule
pp. 163-167(5)
Authors: Pawlotsky, F.; Thomas, A.; Kergueris, M.F.; debillon, T.; Roze, J.C.

Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor
pp. 169-172(4)
Authors: Scholze, Juergen; Stapff, Manfred

Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor
pp. 169-172(4)
Authors: Scholze, J.; Stapff, M.

Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration
pp. 173-175(3)
Authors: Hussain, F.N.; Ajjan, R.A.; Moustafa, M.; Weir, N.W.; Riley, S.A.

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease
pp. 176-180(5)
Authors: da Silva, C. M. F.; David, F. L.; Muscará, M. N.; Sousa, S. S.; Ferraz, J. G. P.; de Nucci, G.; Polimeno, N. C.; Pedrazzoli Jr, J.

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease
pp. 176-180(5)
Authors: da Silva, C.M.F.; David, F.L.; Muscara, M.N.; Sousa, S.S.; Ferraz, J.G.P.; de Nucci, G.; Polimeno, N.C.; Pedrazzoli Jr, J.; Junior, J.P.

Possible association between ocular chloramphenicol and aplastic anaemia-the absolute risk is very low
pp. 181-184(4)
Authors: Laporte, J.R.; Vidal, X.; Ballarin, E.; Ibanez, L.